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The peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors which belong to the
superfamily of nuclear hormone receptors. In recent years it turned out that natural as well as synthetic PPAR agonists exhibit
profound antineoplastic as well as rediﬀerentiation eﬀects in tumors of the central nervous system (CNS). The molecular
understanding of the underlying mechanisms is still emerging, with partially controverse ﬁndings reported by a number of studies
dealing with the inﬂuence of PPARs on treatment of tumor cells in vitro. Remarkably, studies examining the eﬀects of these drugs
in vivo are just beginning to emerge. However, the agonists of PPARs, in particular the thiazolidinediones, seem to be promising
candidates for new approaches in human CNS tumor therapy.
Copyright © 2008 Lars Tatenhorst et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. REVIEW CRITERIA
For this review we searched NCBI PubMed articles including
early-releasepublications.Searchtermsincludedperoxisome
proliferator-activated receptor (PPAR) in conjunction with
“glioma” or “glioblastoma” or “astrocytoma” or “neuroblas-
toma.” The abstracts of retrieved citations were reviewed and
prioritized by relevant content. Full articles were obtained
and references were checked for additional material when
appropriate. Only papers published in English between 1995
and 2008 were included.
2. PPARs
The peroxisome proliferators-activated receptors (PPARs)
are ligand-inducible transcription factors which belong to
the superfamily of phylogenetically related proteins termed
nuclear hormone receptors (NHRs). Three diﬀerent PPAR
isotypes (PPARα,P P A R β, also called δ,a n dP P A R γ)h a v e
been identiﬁed in various species and show structural
homology [1, 2]. PPARγ is found in two diﬀerent isoforms,
PPARγ1a n dP P A R γ2[ 3].
PPARα,P P A R β/δ and PPARγ show unique spatio-
temporal tissue-dependent patterns of expression during
fetal development in a broad range of cell types with
ectodermal, mesodermal, or endodermal origin. PPARs are
involved in several aspects of tissue diﬀerentiation and
development,suchasthediﬀerentiationoftheadiposetissue,
brain, placenta, and skin [4]. Therefore, it appears that
the PPAR isoforms developed from a common PPAR gene
with broad ligand-binding speciﬁcity, itself derived from the
ancestral orphan receptor [5].
PPARs regulate gene expression via multiple mecha-
nisms, thereby functioning as obligate heterodimers with
retinoid-X-receptors (RXRs). Like the other members of the
NHR superfamily, PPARs are composed of four domains.
The highly conserved DNA-binding domain together with
its zinc ﬁnger domain is a common attribute of all family
members. The DNA binding domain is linked to the C-
terminalligandbindingdomainbythehingeregion.TheE/F
domain is responsible for the dimerization of PPARs with
RXRs and the ligand-dependent transactivation function of
the receptor. The N-terminal domain ﬁnally is involved in
the ligand-independent regulation of the receptor activity
(reviewed in [6]).2 PPAR Research
PPARs stimulate gene expression through binding to
conserved DNA sequences, termed peroxisome-proliferator
response elements (PPREs), present in the promoter region
of their target genes. In the absence of ligands, these
heterodimersarephysicallyassociatedwithcorepressorcom-
plexes whichsuppress genetranscription [4].However, upon
binding of a ligand to the receptor, the NCor-containing
corepressor complexes are dismissed and replaced with
coactivator complexes. These coactivators are then linked to
the basal transcriptional apparatus, thereby activating gene
transcription [7].
PPARs act prinicipally as lipid sensors and regulate
whole body metabolism in response to dietary lipid intake
and direct their subsequent metabolism and storage [8].
The prototypic member of the family, PPARα, was initially
reported to be induced by peroxisome proliferators, and
now denotes the subfamily of three related receptors. The
natural ligands of these receptors are dietary lipids and
their metabolites. The speciﬁc ligands interacting with the
individual receptors have been diﬃcult to establish, owing
to the relatively low-aﬃnity interactions and broad ligand
speciﬁcity of the receptors.
PPARα acts primarily to regulate energy homeostasis
through its ability to stimulate the breakdown of fatty
acids and cholesterol, driving gluconeogenesis and reduction
in serum triglyceride levels. This receptor acts as a lipid
sensor, binding fatty acids and intiating their subsequent
metabolism. PPARα binds a number of lipids including
fatty acids, eicosanoids, and other natural lipid ligands. Its
dominantactionistostimulateadipocytediﬀerentiationand
to direct lipid metabolites to be deposited in this tissue.
PPARγ operates at the critical metabolic intersection of lipid
and carbohydrate metabolism. PPARγ activation is linked
to reduction in serum glucose levels, likely as a secondary
eﬀect of its ability to regulate endocrine factors. It is this
latter activity that has led to the development of speciﬁc
PPARγ agonists for the treatment of type-2 diabetes [9]. The
PPARβ/δ binds and responds to VLDL-derived fatty acids,
eicosanoids including prostaglandin A1 [10] and appears to
be primarily involved in fatty acid oxidation, particularly in
muscle.
Binding of PPARs to their speciﬁc ligands leads to
conformational changes which allow co-repressor release
and co-activator recruitment. Even though all PPARs can
be attributed to a common ancestral nuclear receptor,
each PPAR isotype has its own properties with regard
to ligand binding. Synthetic thiazolidinediones (TZDs),
which are commonly prescribed for the treatment of type-
2 diabetes, are selective PPARγ ligands. Naturally occurring
PPARγ ligands include eicosanoids and the cyclopentenone
prostaglandin 15d-PGJ2. The best characterized PPARγ
agonists are the TZDs including pioglitazone (Actos) and
rosiglitazone (Avandia), which are Food and Drug Associa-
tion (FDA) approved for treatment of type-2 diabetes. The
TZD troglitazone (Rezulin) was introduced in the late 1990s
butturnedouttobeassociatedwithanidiosyncraticreaction
leadingtodrug-inducedhepatitis.Itwaswithdrawnfromthe
US market in 2000, and from other markets soon afterwards.
Thereareanumberofnon-TZD-basedPPARγ agonists,such
as GW78456 and others that have been developed. PPARα
ligands include ﬁbrates that are commonly used for the
treatment of hypertriglyceridemia and the synthetic agonists
WY14,643 and GW7647. PPARβ/δ agonists include the
prostacyclin PGI2, and synthetic agents including GW0742,
GW501516, and GW7842. All three PPAR isotypes can
be activated by polyunsaturated fatty acids with diﬀerent
aﬃnities and eﬃciencies [8, 11]. An overview addressing
the aﬃnity of several natural and synthetic ligands has been
summarized recently [12].
All PPARs have been described in the adult and develop-
ing brain as well as in the spinal cord. Furthermore, it has
been suggested that PPAR activation in neurons may directly
inﬂuence neuron cell viability and diﬀerentiation [13–17].
While PPARβ/δ has been found in neurons of numerous
brain areas, PPARα and γ have been localized to more
restricted brain areas [18, 19]. The localization of PPARs
has also been investigated in puriﬁed cultures of neural cells.
PPARβ/δ is expressed in immature oligodendrocytes where
its activation promotes diﬀerentiation, myelin maturation
and turnover [20, 21]. The γ isotype is the dominant isoform
in microglia. Astrocytes possess all three PPAR isotypes,
although to diﬀerent degrees depending on the brain area
and animal age [22, 23].
The role of PPARs in the CNS is mainly related to lipid
metabolism; however, these receptors have been implicated
in neural cell diﬀerentiation and death as well as in
inﬂammation and neurodegeneration. The expression of
PPARγ inthebrainhasbeenextensivelystudiedinrelationto
inﬂammation and neurodegeneration [14]. PPARα has been
suggestedtobeinvolvedintheacetylcholinemetabolism[24]
and tobe related toexcitatory amino acid neurotransmission
and oxidative stress defense [18]. However, mice lacking
PPARα function appear healthy and fertile and do not
show neurological phenotypes, suggesting that PPARα is
dispensable for brain development [25]. In contrast, loss
of PPARγ has been shown to be embyonically lethal [26].
Whereas PPARβ/δ remains highly expressed in the rat CNS,
the expression of PPARα and γ decreases postnatally in
the brain [27]. In retina, all three receptors are expressed
[23, 27, 28]. Even though this pattern of expression, which is
isotype-speciﬁc and regulated during development, suggests
that the PPARs may play a role during the formation
of the CNS, their function in this tissue is still poorly
u n d e r s t o o d .B o t hi nv i t r oa n di nv i v oo b s e r v a t i o n ss h o w
that PPARβ/δ is the prevalent isoform in the brain beeing
found in all cell types, whereas PPARα is expressed at
very low levels predominantly in astrocytes [29]. Acyl-CoA
synthetase 2, which is crucial in fatty acid utilization, is
regulatedbyPPARβ/δ atthetranscriptionallevel,providinga
facile measure of PPARβ/δ action. This observation strongly
suggests that PPARβ/δ participates in the regulation of
lipid metabolism in the brain. This hypothesis is further
supportedbytheobservationthatPPARβ/δ nullmiceexhibit
an altered myelination of the corpus callosum. Such a defect
was not observed in other regions of the central nervous
system, and the expression of mRNA encoding proteins
involved in the myelination process remained unchanged in
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As mentioned above, PPARs were at ﬁrst identiﬁed as
controllers of lipid metabolism. Presently, it turned out that
PPARs also play a role in controlling important cellular
functions like energy homeostasis, diabetes, cell proliferation
and cell death, diﬀerentiation, inﬂammation, and even
cancer [6, 31]. Especially PPARγ and its agonists have been
demonstratedtoinduceantineoplasticeﬀectsinseveraltypes
of cancer (reviewed in [7]). In the following we focus on the
role of PPARs as potential inducers of antineoplastic eﬀects
in highly abundant CNS tumors, namely astroglioma and
neuroblastoma.
3. ASTROGLIOMA
Malignant astrocytic gliomas represent the largest propor-
tion of all primary brain tumors in adults [32, 33]. The
characteristic feature of glioma cells is a high proliferation
rate, accompanied by the ability to invade far into the
healthy brain tissue. According to the WHO classiﬁcation
of tumors of the nervous system [32], gliomas are ranked
with increasing malignancy in four classes from WHO
grade I to WHO grade IV. The vast resistance against
irradiation and chemotherapy and the prevalent recurrence
after surgical resection are the main reasons for the poor
prognosis in treatment of malignant astrocytic gliomas.
Despite multimodal therapeutic approaches, the mean sur-
vival time of patients with WHO grade IV glioblastoma
multiforme, which is also the most frequent brain tumor, is
only about one year after diagnosis [33]. Although medical
research has been intensiﬁed in the past decades, the overall
survival of patients with malignant astrocytic gliomas was
not essentially improved [34].
All isoforms of PPARs are expressed in the brain [35, 36]
as well as in a variety of rat and human astroglial cell lines [7,
37–44]. PPARγ has been shown to be expressed at high levels
inhumanglioblastomas[31,37,45,46].Basedonﬁndingsin
otherneoplasticdisease,severalnaturalandsyntheticligands
of PPARs have been tested for their eﬃcacy in the treatment
of astroglioma. Bezaﬁbrate and gemﬁbrozil, both PPARα
agonists, inhibited the cellular viability of glioblastoma cell
lines [47]. A diﬀerent eﬀect was observed when human
T98G glioblastoma cells were treated with other PPARα
ligands, cloﬁbrate and Wy-14,643. These ligands strongly
downregulated the expression of semaphorin 6B, a member
of the semaphorin family of axon guidance molecules [39],
suggesting suppression of glioma invasion mechanisms by
these PPARα agonists. However, no direct inﬂuence of Wy-
14,643 on proliferation or induced cell death was observed
in either human or rat glioma cells [43].
Treatment with conjugated linoleic acid (CLA) inhibited
growth in primary human glioblastoma cells as well as
ADF glioblastoma cells [13, 40, 48]. In ADF cells this was
associated with an increase of PPARα and a decrease of
PPARβ/δ expression, whereas PPARγ levels were unaltered
[40]. Cimini et al. found that CLA and the PPARγ-speciﬁc
agonist GW347845 reduced glioma cell growth and induced
apoptosis [13, 48]. The authors suggested that this eﬀect was
mediated by PPARγ activation. This conclusion was sup-
ported by the ﬁnding that the PPARγ antagonist GW259662
completely prevented both the CLA and GW347854X-
induced eﬀects on cell growth and apoptosis. Furthermore,
PPARγ agonists reduced cell adhesion, cell migration, and
tumor invasion which was associated with a decrease in
matrix metalloproteinase 2 (MMP2) levels. The authors
stated that activation of PPARγ is likely to be responsible for
these latter eﬀects, since the PPARγ antagonist GW259662
completely abolished these eﬀects [13]. Furthermore, treat-
ment with CLA and GW347845 signiﬁcantly decreased
VEGF isoforms, indicating that PPARγ may also inhibit
angiogenesis in gliomas [48].
P´ erez-Ortiz et al. reported that generation of reactive
oxygen species (ROSs) was likely to be responsible for
glitazone-induced glial cell death [35, 49], which is in
line with ﬁndings of Kang et al. [50]. Interestingly, in
four diﬀerent glioma cell lines (A172, U87-MG, M059K,
M059J) rosiglitazone led to inhibition of proliferation and
induction of apoptosis in a PPARγ-dependent way since
there the antagonist GW9662 partially reverted this eﬀect
[46].CiglitazoneandtheputativenaturalPPARγ ligandPGJ2
inhibited proliferation and induced apoptotic cell death in
human [38] and rat glioma cells, and apoptotic cell death
was correlated with the upregulation of Bax and Bad protein
levels [43]. Similar eﬀects have been described by Zang et al.
[44], who also reported that a combination of pioglitazone
with all-trans retinoic acid (ATRA) increased the cytotoxic
eﬀect. Tetradecylthioacetic acid (TTA), a saturated fatty acid
and PPAR ligand, inhibited growth of BT4Cn rat glioma
cells at increased levels as compared to the PPARγ ligand
rosiglitazone [37]. Furthermore, TTA reduced tumor growth
and led to a longer survival of rats with implanted BT4Cn
tumors. The use of the PPARγ antagonist GW9662 reversed
the eﬀect of rosiglitazone but not for TTA, indicating that
TTA might act both via PPARγ-dependent and PPARγ-
independent pathways [37].
Grommes et al. reported that the nonthiazolidinedione
tyrosine-based PPARγ ligand GW7845 reduced viability of
rat C6 and human glioma cells and induced apoptotic cell
death in a PPARγ-dependent mechanism as shown by the
inhibition of these eﬀects by the speciﬁc antagonist GW9662
[51]. Primary astrocytes were not aﬀected, demonstrating
the speciﬁcity of the eﬀects of GW7845 on neoplastic cell
types. GW7845 also reduced proliferation of rat C6 glioma
cells and reduced both the migration and invasion of glioma
cells [51]. These investigators have subsequently reported
[52] that the PPARγ agonist pioglitazone reduced cellular
viability of rat and human glioma cell in vitro. Furthermore
proliferation in rat glioma cells was inhibited, as measured
by Ki-67 expression. Glioma cells overexpressing PPARγ-
cDNA showed reduced cellular viability after pioglitazone
treatment, whereas treatment of glioma cells overexpressing
a mutant cDNA lacking transcriptional activity, showed
no antineoplastic eﬀects [52]. Grommes et al. extended
these ﬁndings to in vivo studies, using a C6 rat glioma
model [52]. In this study, tumor volumes were dramatically
reduced following pioglitazone administration intracere-
brally, as well as orally, indicating that pioglitazone is able
to cross the blood-brain barrier (BBB). It has not been
established whether TZDs other than pioglitazone penetrate4 PPAR Research
















































the BBB. However, in vitro studies provide evidence that
troglitazone is actively incorporated by the bidirectional
transporter Oatp14 (Slco1c1) expressed in brain capillary
endothelial cells, which is likely to provide homeostasis of
troglitazone and may be of other TZDs [53]. Treated animals
showed drug-induced apoptosis in the tumors by activation
of proapoptotic proteins. Grommes and coworkers also
observed decreased tumor invasion in vivo which was cor-
related with reduced MMP9 levels. Indeed, PPARγ agonists
suppressed tumor migration in vitro in a Boyden cham-
ber assay. Finally, they described a pioglitazone-induced
upregulation of the astrocytic rediﬀerentiation marker CS-
56 in tumor cells both in vivo and in vitro. Primary
astrocytes were not aﬀected by pioglitazone, indicating the
restriction of these eﬀects to neoplastic cell types [52]. A
possible explanation for this neoplastic speciﬁcity is given
by Spagnolo et al., who showed diﬀerences in metabolic
responses in GL261 glioma cells as compared to primary
astrocytes when treated with the TZD troglitazone [54].
The same authors also presented a study exploring
C57/Bl6 mice with an intracerebral glioma derived from
GL261 cells [55]. Mice were treated with a combined
therapy of interleukin (IL)-2-secreting syngeneic/allogeneic
ﬁbroblasts administered into the tumor bed along with the
TZD pioglitazone. In contrast to the data of Grommes et al.,
onlyintracerebrallyadministeredpioglitazoneprolongedthe
survival of mice harboring an intracerebral glioma, whereas
pioglitazone administered orally showed no eﬀect. Finally,
combination of pioglitazone and Il-2-secreting ﬁbroblasts
signiﬁcantly prolonged the survival of the treated mice as
compared to untreated animals [55].
Using an organotypic glioma invasion model, closely
resembling extracellular matrix environment present in
the brain, Coras et al. show that micromolar doses of
troglitazone blocked glioma progression without neurotoxic
damage to the organotypic neuronal environment observed
[56]. The authors stated that the intriguing antiglioma
property of troglitazone appears to be only partially based
on its moderate cytostatic eﬀects. Concordant with the
data presented by Grommes et al., the authors showed
that troglitazone eﬀectively inhibits glioma cell migration
and brain invasion. Interestingly, the antimigratory eﬀects
of troglitazone could be mimicked by inhibition of TGF-
ß signaling which has shown to be intimately involved in
glioma cell migration, suggesting both mechanisms to be
interlinked. In this study, the authors identiﬁed troglitazoneLars Tatenhorst et al. 5
as a potent inhibitor of TGF-ß release, suggesting that
troglitazone reduced glioma cell motility by counteracting
TGF-ß signaling [56].
Morethan10yearsago,Prasannaetal.[57]reportedthat
treatment with lovastatin (a HMG-CoA reductase inhibitor)
led to growth arrest in glioma cells, accompanied with
an increased expression of PPAR. A combination therapy
of lovastatin and the PPARγ agonist troglitazone reduced
cellular viability in the DBTRG-05MG human glioblastoma
cell line [58]. Interestingly, the combination of lovastatin
withtwootherPPARγ agonists,rosiglitazoneandciglitazone,
did not lead to the same eﬀect. The authors suggested that it
may be possible that PPARγ is an essential, but not suﬃcient,
factor in this synergism.
PPAR agonists have also been shown to exhibit eﬀects
on tumor biology through PPAR-independent mechanisms.
For example, the PPARα/γ dual agonist TZD 18 inhibited
growth of T98G human glioblastoma cells and induced
apoptosis through PPAR-independent mechanisms, since
their respective antagonists MK-886 and GW9662 did not
reverse this eﬀect [59]. The TZD-mediated antineoplastic
properties from PPARγ was argued to arise from oﬀ-
target, receptor-independent actions of the drugs as well
as those of rosiglitazone and pioglitazone [35, 38, 43, 60].
The glitazones were toxic for the human glioma cell line
U251 and rat glioma cell line C6, but not for primary rat
astrocytes [43]. Indeed, PPARγ seems not to be involved in
these eﬀects of the TZDs, since the inhibitor GW9662 had
nearly no eﬀect on attenuation of cytotoxicity. Using PPARγ
positive and PPARγ deﬁcient mouse embryonic stem (ES)
cells, it has been demonstrated that the TZD troglitazone
inhibited the growth of tumors formed by injection of
PPARγ+a n dP P A R γ− cells to the same extent, indicating
that PPARγ is not essential for the antiproliferative eﬀects of
troglitazone [60]. Moreover, troglitazone derivatives which
are unable to activate PPARγ suppress cancer cell prolifer-
ation similar to troglitazone, giving further evidence that
the antiproliferative eﬀects of troglitazone are at least in
part PPARγ-independent [61]. Furthermore, troglitazone
sensitized human glioma cells to TRAIL-induced apoptosis
in a process independent of PPARγ [62, 63]. Troglitazone
treatment led to a marked downregulation of the antiapop-
totic proteins FLIP and survivin [63]a sw e l la sB c l - 2[ 62]
and so could possibly counteract the capability of tumor
cells to become resistant to apoptosis. Hence a combination
therapy of troglitazone and TRAIL might be a promising
experimental approach. Conversely, in A172 human glioma
cells Kang and colleagues showed that the TZD ciglitazone
induced cell death dependent of PPARγ, but independent
of caspase and AIF. Furthermore, the authors demonstrated
that downregulation of XIAP and survivin is involved in
the cell death mechanism [50]. A possible explanation for
the diﬀerentiative eﬀects of PPARγ agonists was supposed
to rely on PPARγ dysfunction. Single strand conformational
polymorphism (SSCP) analysis was carried out in diﬀerent
tumor and nontumor tissues, showing somatic loss-of-
function mutations in diﬀerent carcinomas [64, 65]. Genetic
analysis of American patients with glioblastoma multiforme
revealed an overrepresentation of the H449H polymor-
phism in the PPARγ gene, possibly being an important
low penetrance susceptibility locus for glioneural tumors
[66].
4. NEUROBLASTOMA
Neuroblastoma is a phenotypically heterogeneous tumor,
containing cells of neuronal, melanocytic or glial/Schwann
cell lineage. Regardless of the phenotype, PPARγ is expressed
in neuroblastoma cell lines [67], in primary neuroblastoma
cells [7] as well as in samples of patients harbouring
neurblastoma [68]. Data about the expression of PPARβ/δ
in neuroblastomas are scarce [69–71], and only a few studies
report the expression of PPARα at mRNA or protein level
in human neuroblastoma cell lines [71–74]. Therefore, most
studies that assess the inﬂuence of PPARs on treatment of
neuroblastoma evaluate the impact of its natural or synthetic
ligands.
The putative natural PPARγ agonist 15d-PGJ2 inhibits
cellulargrowth,decreasescellularviabilityandinducesapop-
tosis in human neuroblastoma cells in vitro [67, 69, 74–76].
Rodway et al. [74] show that the PPARα agonist WY-14643
has no eﬀect on the growth of the IMR32 neuroblastoma cell
line, whereas PGJ2 induces growth inhibition in the same
neuroblastoma cells. This occurs through programmed cell
death type II or autophagy, and the serum lysolipid LPA
is responsible for modulating this cellular response. In the
neuroblastomacelllineND-7,thesamegroupshowsthatthe
degree of PPARγ activation induced by PGJ2 is modulated
through an interaction with retinoblastoma protein (Rb)
and the class I histone deacetylase 3 (HDAC3) [75]. A
combination therapy consisting of PGJ2 and the histone
deacetylase inhibitor trichostatin A (TSA) enhanced the
growth inhibition eﬀects and is therefore proposed as a
promising new strategy in the treatment of neuroblastoma.
It should be noted that the eﬀects of 15d-PGJ2 can also arise
from its actions on the NFκBp a t h w a y[ 77]. Di Loreto et
al. report that a speciﬁc PPARβ agonist as well as oleic acid
induced rediﬀerentiation in SH-SY5Y neuroblastoma cells
[70].
The best studied synthetic PPARγ agonists are the TZD
class of antidiabetic drugs, also referred to as glitazones
[7]. Valentiner et al. [78] tested four glitazones (ciglitazone,
pioglitazone, troglitazone, rosiglitazone) and reported their
invitroeﬀectsoncellgrowthinsevenhumanneuroblastoma
cell lines (Kelly, LAN-1, LAN-5, LS, IMR-32, SK-N-SH, SH-
SY5Y). All the glitazones inhibited cell growth and viability
of the human neuroblastoma cell lines in a dose-dependent
manner, whereas the eﬀectiveness of the single drugs diﬀered
strongly between cell lines. Similar results for ciglitazone
and rosiglitazone have been reported [75, 79]. Cellai et al.
show that high concentrations of rosiglitazone signiﬁcantly
inhibit cell adhesion in vitro, invasiveness and apoptosis in
SK-N-AS, but not in SH-SY5Y human neuroblastoma cells
[79]. The authors argued that this eﬀect may be related to
cellular diﬀerences in PPARγ transactivation. Furthermore,
Jung et al. report that the TZD rosiglitazone protects SH-
SY5Y cells against MPP+ as well as acetaldehyde-induced
cytotoxicity, which may be ascribed to the induction of the6 PPAR Research
expression of antioxidant enzymes and also to the regulation
of Bcl-2 and Bax expression by rosiglitazone [80, 81].
5. CONCLUSION
The understanding of the molecular mechanisms underlying
the antineoplastic eﬀects mediated by PPAR agonists is
still emerging. Over the past years, an increasing number
of reports were published, presenting evidence for several
involved pathways concerning cell cycle arrest, apoptosis,
rediﬀerentiation and inhibition of invasion/migration, that
have been found to be aﬀected by PPAR agonist treatment.
Figure 1 presents an overview of signal mechanisms involved
in the antineoplastic eﬀects of PPAR ligands. Interestingly,
therearepartiallycontroverseﬁndingsregardingthereceptor
dependency of the observed eﬀects. Besides the number of
natural and synthetic ligands, as well as to the number of
diﬀerent tumor cell lines used, a further explanation may
be that most studies were performed on long-term cultured
cell lines which may have undergone alterations while being
in cell culture. Only few studies use primary cell cultures of
tumor cells or organotypic models, like Benedetti et al. or
Coras et al. [48, 56], trying to resemble natural conditions as
close as possible. Remarkably, studies examining the eﬀects
of PPAR agonists in vivo are just emerging for gliomas
[52, 55], and are still missing for neuroblastomas.
From all natural and synthetic PPAR ligands, the group
of thiazolidinediones is the one with the best character-
ized antineoplastic properties. The fact that TZDs like
pioglitazone (Actos) and rosiglitazone (Avandia) are FDA-
approved for treatment of type-2 diabetes and therefore
readily available for clinical studies may be the main reason
for this. Very recently, a phase 2 clinical study was published,
presenting for the ﬁrst time a combination of low-dose
chemotherapy with COX-2 inhibitors and PPARγ agonists
in high-grade gliomas [82]. Unfortunately, the trial had
to be closed prematurely, due to the moderate eﬃcacy as
compared to other clinical trials, which however investigated
PPARγ agonist treatment of diﬀerent tumor entities. It is
questionable whether the tumor biology of astroglioma,
which are extremely heterogeneous and rarely metastasize,
can be compared to these diﬀerent tumors, and thus the
degree of response to a PPARγ agonist-based therapy. Of
note, depending on the particular astroglioma and region
within the tumor, the poor blood brain barrier penetration
of the TZDs may also account for limited eﬃcacy. Therefore,
furtherinvivostudiesarewarrantedtounravelthemolecular
mechanisms underlying the antineoplastic eﬀects of PPAR
agonists in malignant astrocytic gliomas.
Nevertheless, agonists of PPARs, in particular the TZDs,
seem to be promising candidates for new therapeutic
approaches in human CNS tumor therapy due to their
profound antiproliferative and anti-invasive eﬀects as well as
their positive eﬀects on apoptosis and rediﬀerentiation.
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